SpyGlass Pharma, Inc. Common Stock
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- SpyGlass Pharma, Inc. is a late-stage biopharmaceutical company focused on transforming chronic eye disease care through durable, long-acting drug delivery solutions. The company specializes in embedding approved ophthalmic medications into proprietary sustained-release platforms to reduce treatment burden for patients and clinicians. Main Products and Services: - BIM-IOL System: an integrated glaucoma therapy delivered during standard cataract surgery, combining intraocular lens implantation with sustained-release glaucoma medication. - BIM-DRS: a broad glaucoma drug-delivery system that extends beyond cataract procedures to enable long-term disease management in a wider patient population. - SpyGlass Drug Delivery Platform: a modular technology designed to incorporate approved drugs into sustained-release formulations for various ophthalmic diseases. - Pipeline programs and feasibility studies: ongoing exploration of additional indications and companion therapies incorporating known drugs with established delivery devices to address chronic eye conditions such as age-related macular degeneration, chronic uveitis, and postoperative care needs. Geographic Operations and Markets: - Headquarters: Aliso Viejo, California, United States. - Primary market: United States, with clinical development activities and potential geographic expansion in other ophthalmology-focused markets. Founding and Corporate Structure: - Founded: 2019 - Public listing: trades on NASDAQ as SGP; information sources indicate ongoing relationships with public market investors and disclosure in line with U.S. regulatory requirements. - Subsidiaries and affiliates: operates as a single corporate entity centered on ophthalmic drug-delivery platforms, with potential collaborations and partnerships as part of a broader strategic program. Latest Major Company Changes: - Strategic partnerships and collaborations to advance sustained-release ophthalmic therapies (including integration into surgical workflows) and broader application of the BIM platforms across glaucoma and other chronic eye diseases. - Advancements in the BIM-IOL and BIM-DRS programs, including potential expansions into additional disease indications and ongoing feasibility studies for long-acting therapies. - Product development pivots toward scaling sustained-delivery technology across therapeutic indications and integrating with established surgical procedures to broaden patient access and outcomes. Industry context and positioning: - Industry: biotechnology and pharmaceutical, with a focus on ophthalmology and drug-delivery technologies. - Business segments: ophthalmic drug delivery platforms, surgical integration products, and pipeline development targeting chronic eye diseases. - Customer types: surgeons, ophthalmology clinics and hospitals, and pharmaceutical partners seeking durable delivery solutions for approved medications.
SpyGlass Pharma Appoints Shannon Treviño as General Counsel
SpyGlass Pharma Appoints Mike Pinder as Vice President, Marketing
SpyGlass Pharma to Participate in Upcoming Investor Conferences
SpyGlass Pharma Announces New Add-on Category III CPT Code for Its Innovative BIM-IOL System
SpyGlass Pharma Reports First Quarter 2026 Financial Results and Provides Corporate Updates
Analyzing Longevity Health (NASDAQ:XAGE) and Spyglass Pharma (NASDAQ:SGP)
Spyglass Pharma, Inc. (NASDAQ:SGP) Receives $45.00 Average PT from Brokerages
SpyGlass Pharma Reports Fourth Quarter and Full Year 2025 Earnings and Provides a Corporate Update
Comparing Spyglass Pharma (NASDAQ:SGP) & Nanovibronix (NASDAQ:FEED)
Longevity Health (NASDAQ:XAGE) and Spyglass Pharma (NASDAQ:SGP) Financial Comparison
SpyGlass Pharma Announces Positive Topline 12-Month Phase 1/2 Trial Results for Its Innovative BIM-IOL System
Spyglass Pharma, Inc. (NASDAQ:SGP) Receives $47.00 Average Target Price from Analysts
SpyGlass Pharma to Participate in the Jefferies Biotech on the Beach Summit
3 Macro Charts That Matter Now: U.S. Dollar, Gold, S&P 500
Here Are Tuesday’s Top Wall Street Analyst Research Calls: Block, CrowdStrike, Fortinet, MongoDB, Mosaic, Palo Alto Networks, Unity Software, and More
Reddit, KKR, and 2 Biotech IPOs Seeing the Love From Insiders
Market Today: Tech Sells Off on AI Jitters; M&A, FDA Moves and Policy Shifts
First Look: McDonald's beats, Hims sued, WBD deal battle
Market Today: Jobs Beat Sways Stocks; MCD, WBD in Focus
First Look: Jobs Data Looms; WBD-NFLX Fight, Moderna Setback